TY - JOUR T1 - Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome JF - medRxiv DO - 10.1101/2020.03.23.20041467 SP - 2020.03.23.20041467 AU - Matthew C Sims AU - Louisa Mayer AU - Janine H Collins AU - Tadbir K Bariana AU - Karyn Megy AU - Cecile Lavenu-Bombled AU - Denis Seyres AU - Laxmikanth Kollipara AU - Frances S Burden AU - Daniel Greene AU - Dave Lee AU - Antonio Rodriguez-Romera AU - Marie-Christine Alessi AU - William J Astle AU - Wadie F Bahou AU - Loredana Bury AU - Elizabeth Chalmers AU - Rachael Da Silva AU - Erica De Candia AU - Sri V V Deevi AU - Samantha Farrow AU - Keith Gomez AU - Luigi Grassi AU - Andreas Greinacher AU - Paolo Gresele AU - Dan Hart AU - Marie-Françoise Hurtaud AU - Anne M Kelly AU - Ron Kerr AU - Sandra Le Quellec AU - Thierry Leblanc AU - Eva B Leinøe AU - Rutendo Mapeta AU - Harriet McKin-ney AU - Alan D Michelson AU - Sara Morais AU - Diane Nugent AU - Sofia Papadia AU - Soo J Park AU - John Pasi AU - Gian Marco Podda AU - Man-Chiu Poon AU - Rachel Reed AU - Mallika Sekhar AU - Hanna Shalev AU - Suthesh Sivapalaratnam AU - Orna Steinberg-Shemer AU - Jonathan C Stephens AU - Robert C Tait AU - Ernest Turro AU - John K M Wu AU - Barbara Zieger AU - NIHR BioResource AU - Taco W Kuijpers AU - Anthony D Whetton AU - Albert Sickmann AU - Kathleen Freson AU - Kate Downes AU - Wendy N Erber AU - Mattia Frontini AU - Paquita Nurden AU - Willem H Ouwehand AU - Remi Favier AU - Jose A Guerrero Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/27/2020.03.23.20041467.abstract N2 - Gray platelet syndrome (GPS) is a rare recessive disorder caused by variants in NBEAL2 and characterized by bleeding symptoms, the absence of platelet ɑ-granules, splenomegaly and bone marrow (BM) fibrosis. Due to its rarity, it has been difficult to fully understand the pathogenic processes that lead to these clinical sequelae. To discern the spectrum of pathological features, we performed a detailed clinical genotypic and phenotypic study of 47 GPS patients. We identified 33 new causal variants in NBEAL2. Our GPS patient cohort exhibited known phenotypes, including macro-thrombocytopenia, BM fibrosis, megakaryocyte emperipolesis of neutrophils, splenomegaly, and elevated serum vitamin B12 levels. We also observed novel clinical phenotypes; these include reduced leukocyte counts and increased presence of autoimmune disease and positive autoantibodies. There were widespread differences in the transcriptome and proteome of GPS platelets, neutrophils, monocytes, and CD4-lymphocytes. Proteins less abundant in these cells were enriched for constituents of granules, supporting a role for Nbeal2 in the function of these organelles across a wide range of blood cells. Proteomic analysis of GPS plasma showed increased levels of proteins associated with inflammation and immune response. One quarter of plasma proteins increased in GPS are known to be synthesized outside of hematopoietic cells, predominantly in the liver. In summary, our data demonstrate that, in addition to the well-described platelet defects in GPS, there are also immune defects. The abnormal immune cells may be the drivers of systemic abnormalities, such as autoimmune disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementM.C.S and J.H.C. are supported by MRC Clinical Research Training Fellowships (MR/R002363/1 and MR/P02002X/1). L.M. is supported by a PhD Studentship grant from the Rosetrees Trust. T.K.B was supported by NHS Blood and Transplant and the British Society for Haematology. D.S. was in part funded by an Isaac Newton Trust/Wellcome Trust Institutional Strategic Support Fund fellowship to M.F., L.K., and A.S. acknowledge support by the Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen, the Regierende Bürgermeister von Berlin - inkl. Wissenschaft und Forschung, and the Bundesministerium für Bildung und Forschung. L.B. was supported by a fellowship from Fondazione Umberto Veronesi. P.G. was supported by a Telethon Foundation Grant (GGP15063). K.F. is supported by the Research Council of the KULeuven (C14/19/096) and by unrestricted grants of Swedish Orphan Biovitrum AB, Bayer and CSL Behring. M.F. is supported by the British Heart Foundation (FS/18/53/33863). This work was performed using resources provided by the Cambridge Service for Data Driven Discovery (CSD3) operated by the University of Cambridge Research Computing Service, provided by Dell EMC and Intel using Tier-2 funding from the Engineering and Physical Sciences Research Council (EP/P020259/1), and DiRAC funding from the Science and Technology Facilities Council.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRNA-seq data has been deposited in the European Genome-phenome Archive under study accession number ID EGAD00001005950. All newly identified NBEAL2 variants have been deposited in ClinVar. Cell-type specific and plasma proteomics results have been deposited to the ProteomeXchange Consortium via the PRIDE repository at EMBL-EBI with the dataset identifiers PXD016366 and PXD017227, respectively. https://www.ebi.ac.uk/ega/datasets/EGAD00000000021 https://www.ebi.ac.uk/pride/ ER -